(Q46459086)

22 December 2017

title

Treatment of neurocysticercosis: is it beneficial? (English)

1 reference

22 December 2017

1 reference

Ravindra Kumar Garg

1

1 reference

22 December 2017

publication date

1 August 2008

1 reference

22 December 2017

Expert Review of Anti-infective Therapy

published in

1 reference

22 December 2017

volume

6

1 reference

22 December 2017

issue

4

1 reference

22 December 2017

page(s)

435-440

1 reference

22 December 2017

Treatment of neurocysticercosis: current status and future research needs

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.4.435

21 January 2018

Identifiers

DOI

10.1586/14787210.6.4.435

1 reference

22 December 2017

PubMed ID

18662110

1 reference

22 December 2017